On the stock market since 2021, it operates in the world of health and science. It has 14 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 10 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $3.00 — 390% above today’s price.
A loss of $66.6M against $0 in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.61. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
On our five-subject report card, BRNS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BRNS is a high-risk stock — not yet profitable, and its future rides on its product catching on.